Preclinical Alzheimer's Disease
16
2
4
7
Key Insights
Highlights
Success Rate
78% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
12.5%
2 terminated out of 16 trials
77.8%
-8.8% vs benchmark
6%
1 trials in Phase 3/4
0%
0 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (16)
AV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980)
Alzheimer's Tau Platform: Master Protocol
Alzheimer's Tau Platform: Regimen A - AADvac1
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
Financial Incentives and Recruitment to the APT Webstudy
Alzheimer's Plasma Extension
TRC-PAD Program: In-Clinic Trial-Ready Cohort
Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech - FUTURE Extension
Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - FUTURE Extension
Prediction of Cognitive Decline by Neuroimaging Techniques and the Application in Diagnosis and Treatment of Preclinical AD
Concurrent Aerobic Exercise and Virtual Reality Cognitive Training
Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - PAST Extension
Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech - PAST Extension
Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping
Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech
Modulation of Micro-RNA Pathways by Gemfibrozil in Predementia Alzheimer Disease